Detalhe da pesquisa
1.
Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
Am Heart J
; 232: 71-83, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33157067
2.
Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.
J Vasc Surg
; 73(5): 1702-1714.e11, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080324
3.
Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.
J Vasc Surg
; 67(2): 637-644.e30, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29389426
4.
Registry Assessment of Peripheral Interventional Devices (RAPID)ã- Registry Assessment of Peripheral Interventional Devices Core Data Elements.
Circ J
; 82(2): 316-322, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29367497
5.
Harmonization by Doing Proposal for Global Clinical Trial Designs for Endovascular Devices for Treatment of Critical Limb Ischemia: The United States Food and Drug Administration Perspective.
Circ J
; 82(12): 3110-3111, 2018 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30381695
6.
Chondroitin sulfate proteoglycans inhibit oligodendrocyte myelination through PTPσ.
Exp Neurol
; 247: 113-21, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23588220